The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.
Menendez criticizes the lack of oversight in the PBM market.
Share
More from Bob Menendez
And what I know about laws is that they can be made stronger and they could also be made weaker.
I feel like that voice is lost. And I think it is something that is critically important to make sure that they are a part of the process.
Other voices in this conversation
